Stock Watch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season
Fewer Acquisitions And Preannounced Revenues Did Not Inspire
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
You may also be interested in...
BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal
BeiGene has teamed up with Novartis to take its PD-1 antibody global after an earlier major deal with Celgene was terminated following the BMS acquisition, and amid intense market and pricing competition in the immuno-oncology sector in China.
Sanofi Hits M&A Trail Again To Buy UK's KyMab
Another UK biotech has been swallowed up by a big pharma with Sanofi acquiring the Cambridge-based firm in a deal that could be worth almost $1.5bn.
AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.